ArticleBulletin of mathematical biology2026
In Silico Comparison of Rifampicin and 25-desacetyl Rifampicin-Induced PXR-Mediated CYP450 Transcriptional Response in 3D Primary Human Hepatocytes.
Article in Bulletin of mathematical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- On the structural identifiability of nonlinear models of ligand binding dynamics.Journal of pharmacokinetics and pharmacodynamics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The pregnane X receptor (PXR) regulates the expression of cytochrome P450 (CYP) enzymes and plays a crucial role in the metabolism of various drugs. Rifampicin (RIF) is a PXR ligand that forms the primary metabolite, 25-desacetyl rifampicin (25-DRIF), which retains the antimicrobial activity of the original drug. In this study, we quantified PXR activation and its associated effects on CYP3A4, CYP2C9, and CYP2B6 enzymes in response to 25-DRIF treatment by combining mathematical modeling with long-term mRNA expression analysis of these enzymes in 3D primary human hepatocyte (3D PHH) spheroids. Our estimates suggest that 25-DRIF activates PXR at a rate 20 times lower than RIF. The PXR-dependent rate constant for CYP3A4 transcription was estimated to be higher in 3D PHHs treated with 25-DRIF than in those treated with RIF and also higher than that for CYP2B6 transcription in 3D PHHs treated with 25-DRIF. The rate constants driving PXR-dependent transcription of CYP2C9 were comparable in RIF- and 25-DRIF-treated 3D PHHs. These results demonstrate the ligand-specific nature of PXR activation and suggest that the transcription of PXR-controlled CYP enzymes is ligand- and CYP-specific in 3D PHHs. Finally, we showed that the half-maximal effective concentration (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.